⌘K

Login Start Free

Home/Filings/4/0001062993-22-007013

4//SEC Filing

Vance Terry 4

Accession 0001062993-22-007013

CIK 0001177648other

View on SEC.gov Company Profile

Filed

Mar 6, 7:00 PM ET

Accepted

Mar 7, 6:52 PM ET

Size

5.2 KB

Accession

0001062993-22-007013

Insider Transaction Report

Form 4

Period: 2022-03-03

ENANTA PHARMACEUTICALS INCENTA

Director

Transactions

Award
Stock Option (right to buy)
2022-03-03+7,500→ 7,500 total
Exercise: $68.22Exp: 2032-03-03→ Common Stock (7,500 underlying)

Footnotes (1)

[F1]Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 3, 2022), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2023 annual meeting of stockholders.

Documents

1 file

4
form4.xmlPrimary
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Issuer

ENANTA PHARMACEUTICALS INC

CIK 0001177648

Entity typeother

Related Parties

1

filerCIK 0001572282

Filing Metadata

Form type: 4
Filed: Mar 6, 7:00 PM ET
Accepted: Mar 7, 6:52 PM ET
Size: 5.2 KB

View on SEC.gov